OncoResponse
Latest round
- Series C
Last raised
- Mar 2021
Total raised
- $90M
Investors
- 15
About OncoResponse
OncoResponse, Inc., founded in 2015 and headquartered in Seattle, US, specializes in cancer immunotherapy development.91 mn.OncoResponse develops novel cancer immunotherapies, focusing on a pipeline of monoclonal antibodies that aim to convert 'cold' tumors into 'hot' ones, thereby improving immune system responses.OncoResponse generates revenue through strategic partnerships and collaborations within the biotech and pharmaceutical sectors. These partnerships often involve joint development agreements that leverage shared resources, alongside milestone payments and royalties based on the success of developed products. The funds will be utilized to advance their pipeline of cancer immunotherapies, targeting specific markets in North America, Europe, and Asia. The company plans to launch new products designed to enhance immunotherapeutic approaches and is committed to expanding its reach within the global oncology market.
Who invested in OncoResponse
15 investors across 6 rounds
See all investors in OncoResponse
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OncoResponse
Who invested in OncoResponse?
OncoResponse has 15 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OncoResponse raised?
OncoResponse has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did OncoResponse last raise money?
OncoResponse's most recent round on record is a Series C, in Mar 2021.
What does OncoResponse do?
OncoResponse is a biotechnology company.
Where is OncoResponse headquartered?
OncoResponse is headquartered in Seattle, US.
Which VCs invest in companies like OncoResponse?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at OncoResponse's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like OncoResponse? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.